Several studies have tested this anti-BRAF therapy in the setting of CRC, but in contrast to the results observed in BRAF V600E melanoma, vemurafenib as a single therapy did not demonstrate any clinically relevant activity in BRAF mutant metastatic CRC [66]. This evidence concerns the gene BRAF and melanoma.